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Abstract
Etk is a non-receptor tyrosine kinase, which provides a strong survival signal in human prostate cancer cells. Src, another
tyrosine kinase that cross-activates with Etk, has been shown to play an important role in prostate cancer metastasis. Herein,
we discovered a new class of Etk inhibitors. Within those inhibitors, CTA095 was identified as a potent Etk and Src dual
inhibitor. CTA095 was found to induce autophagy as well as apoptosis in human prostate cancer cells. In addition, CTA095
inhibited HUVEC cell tube formation and ‘‘wound healing’’ of human prostate cancer cells, implying its role in inhibition of
angiogenesis and metastasis of human prostate cancer. More interestingly, CTA095 could overcome Src inhibitor resistance
in prostate cancer cells. It induces apoptosis in Src inhibitor resistant prostate cancer cells, likely through a mechanism of
down regulation of Myc and BCL2. This finding indicates that simultaneously targeting Etk and Src could be a promising
approach to overcome drug resistance in prostate cancer.
Citation: Guo W, Liu R, Bhardwaj G, Ma A-H, Changou C, et al. (2013) CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and
Overcomes Resistance to Src Inhibitors. PLoS ONE 8(8): e70910. doi:10.1371/journal.pone.0070910
Editor: Qiming Jane Wang, University of Pittsburgh School of Medicine, United States of America
Received March 7, 2013; Accepted June 25, 2013; Published August 15, 2013
Copyright:  2013 Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was in part supported by C-Tag Bioscience Inc (Research grant to RL); NIH grants DK52659 CA150197 (to HJK), and CA098116 (to KSL); and
DOD Postdoctoral Training Award PC080859 and Auburn Community Cancer Endowment Fund (to WG). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: C-Tag Inc is a commercial funder for this work, and both KSL and HJK are scientific advisors for C-TAG Inc. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: rwliu@ucdavis.edu (RL); hkung@ucdavis.edu (HJK)
Introduction
Prostate cancer is the most frequently diagnosed cancer and the
second leading cause of cancer deaths of men in the U.S. [1].
While early phase prostate cancer (CaP) can effectively be
controlled by hormone therapy, metastatic CaP remains incurable.
Tyrosine kinase inhibitors (TKIs) are among the most promising
targeted therapies; yet their potential as prostate cancer therapeu-
tics have not been fully realized and, to date, the outcomes of
clinical trials using TKIs as single agents have generally been
modest, probably due to redundancy in receptor binding and
signaling to intracellular mediators [2]. Most of the TKIs that have
been developed are directed against receptor tyrosine kinases. Etk
is a non-receptor tyrosine kinase, which is over-expressed in
human prostate cancer specimens and provides strong survival
functions in prostate cancer cells [3,4]. Etk mediates critical
activation of STAT3 in CaP suggesting that functional disruption
of Etk may attenuate multiple key signals involved in CaP growth
and survival [5]. Etk also regulates survival [6], metastasis [7],
drug resistance [3,8], angiogenesis [9], and apoptosis [10].
Overexpression of Etk induces prostate intraepithelial neoplasia
in a mouse [11]. Recent reports indicate that Etk plays an
important role in the self-renewal and tumorigenic potential of
glioblastoma stem cells through Stat3 activation [12]. Therefore,
systemic inhibition of Etk may offer synergistic anti-tumor effects.
As of yet, there is no efficacious inhibitor of this kinase.
Src, Etk, and FAK associate with and cross-activate each other.
Inhibition of one often decreases the activity of the others. These
three kinases have been shown to play an important role in
angiogenesis and metastasis of prostate cancer cells. The Src
inhibitor, AZD0530, has been reported to inhibit prostate cancer
bone metastasis in animal models. However, this inhibitor lacks
the activity to induce apoptosis of prostate cancer cells. Dual
inhibition of Etk and Src could not only overcome the
disadvantage of Src inhibitors, but may also increase efficacy in
inhibiting metastasis of prostate cancer cells.
Autophagy is a catabolic process involving the degradation of a
cell’s own components through the lysosomal machinery [13]. It is
a tightly regulated process that helps maintain a balance between
the synthesis, degradation, and subsequent recycling of cellular
products [14]. Autophagy could contribute to both cell survival
and cell killing in a context dependent manner. Autophagy
modulators have now emerged as important sensitizers or
modifiers of targeted therapy [15,16].
Herein, we report identification of a novel Etk and Src dual
inhibitor, CTA095, which induces autophagy and apoptosis, as
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well as synergistic effects with autophagy modulators in prostate
cancer cells. To our knowledge, this is the first report of an Etk and
Src dual inhibitor with an application as an anti-cancer agent.
Materials and Methods
Reagents
Purified Etk, Btk, Mertk, Yes and Src kinases were obtained
from Millipore Inc (Dundee, UK). Propidium Iodide (PI), N,N-
diisopropylethylamine (DIEA), N,N-dimethylformimide (DMF),
ethanol, acetonitrile (ACN), 1-(3-aminopropyl)piperidine, trifluor-
oacetic acid (TFA), Pd/C, ammonium formate and dimethyl
sulfoxide (DMSO) were purchased from Sigma-Aldrich (Saint
Louis, MO). L-Phenylglycine methyl ester hydrochloride was
purchased from Chem-Impex International Inc (Wood Dale, IL).
Dibenzofuran-2-carboxaldehyde was purchased from Oakwood
Products, Inc (West Columbia, SC). The annexin V-FITC
apoptosis detection kit was obtained from Abcam (Cambridge,
MA). Reversed-phase high-performance liquid chromatography
(RP-HPLC) from the Waters Corporation (Milford, MA) was used
for analysis and purification of CTA095. LNCAP, CWR22Rv1,
RWPE1, 293 and HUVEC cells were obtained from ATCC
(Manassas, VA).
One-pot synthesis of CTA095
The synthetic approach of CTA095, 2-(dibenzo[b,d]furan-2-yl)-
7-phenyl-1-(3-(piperidin-1-yl)propyl)-1H-imidazo[4,5-g]quinoxa-
lin-6(5H)-one, is similar to the approach we previously reported
[17]. In brief, a solution of L-Phenylglycine methyl ester
hydrochloride (201.7 mg, 1.0 mmol) and DIEA (383.2 mL,
2.2 mmol) in DMF (1.5 ml) was added dropwise under vigorous
stirring to a solution of 1,5-difluoro-2,4-dinitrobenzene (204.0 mg,
1.0 mmol) in DMF (0.5 ml). The reaction solution was stirred at
room temperature for 45 min. This was followed by the addition
of a solution of 1-(3-aminopropyl) piperidine (159 mL, 1.0 mmol)
and DIEA (174.2 mL, 1.0 mmol) in DMF (1 ml). The resulting
mixture was agitated at room temperature overnight. Ethanol
(20 ml), Pd/C (10%, 200 mg), and ammonium formate (1.50 g,
23.8 mmol) were added to the solution. The solution was heated to
reflux for 3 h and then cooled to room temperature. The Pd/C
was filtered out and the filtrate was concentrated with rotary
evaporator. Dibenzofuran-2-carboxaldehyde (196.2 mg,
1.0 mmol) in DMF was added to the solution. The resulting
solution was stirred at room temperature for 1 day. The DMF
solution was poured into 40 mL of ice. The precipitate was
collected by filtration and washed with water, followed by RP-
HPLC purification. The fraction was collected and lyophilized to
give a yellow powder as the final product (Figure S1). The
Figure 1. CTA095 inhibits Etk activity and PC3 cell growth. Chemical structure of CTA095 (A), identification of CTA095 as a potent Etk inhibitor
(B) and its cytotoxicity to PC3 cells (C). For Etk inhibition, purified Etk (20 nM), the corresponding compounds (1 mM), and the peptide substrate
(YIYGSFK) were incubated with 33P-ATP in a kinase reaction. The resulting product was analyzed on a TLC plate. For growth inhibition, PC3 cells were
seeded at 5,000 cells/well in 96-well plate overnight and treated with the corresponding compounds (10 mM) The cell viability was measured using
MTT assay after 72 h. Columns, mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g001
Etk and Src Dual Inhibitor for Prostate Cancer
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e70910
homogeneity of the compound was checked by analytical RP-
HPLC. The purity was determined to be.95% pure. The identity
of the compounds was confirmed by matrix-assisted laser
desorption/ionization-time of flight mass spectrometry. Found:
554.26 Dalton (calculated: 554.26 Dalton for MH+).
Molecular modeling
Molecular docking studies were performed to understand the
binding of CTA095 to Etk. Energy optimized structure of
CTA095 was calculated using Merck Molecular Force Field
(MMFF) [18], as implemented in Marvin Suite v 5.11 (http://
www.chemaxon.com/products/marvin). The three-dimensional
structure of human Etk (residues 275–675) sequence (NCBI GI:
42544182) was predicted using a homology modeling based
approach as implemented in HHPred [19,20]. To define a
putative binding site for CTA095 on the Etk protein structure, we
first used a blind docking approach implemented on the
SwissDock webservice (http://swissdock.vital-it.ch) [21,22].
Among the clusters generated by SwissDock, the conformation
with the lowest binding free energy was selected. In order to
further understand the stability and dynamics of the ligand-kinase
complex, we performed a 20 ns molecular dynamics (MD)
simulation, starting with the best-docked structure predicted by
SwissDock. These simulations were performed using NAMD v
2.7b2 [23]. CHARMM27 force fields were used to calculate the
potentials of Etk, while CHARMM22 (as implemented in
SwissParam (http://swissparam.ch) [24] force fields were used to
calculate the potentials of CTA095. The kinase-ligand complex
was solvated in a water box with periodic boundary conditions.
Dimensions of the water box were selected to be at least 10
angstroms larger than the solute in every direction. The whole
system was neutralized with 0.15 M NaCl. An initial minimization
step was performed for 6000 steps, followed by 20 ns of relaxation.
Trajectories of these simulations were visualized using VMD v 1.9
[25], and the interactions between kinase and the ligand were
plotted using PyMol and LigPlot+ v 1.4 [26].
Kinase inhibition assay
Kinase inhibition was measured using thin-layer-chromatogra-
phy (TLC). Briefly, purified kinases (20 nM), the corresponding
substrate (500 mM, TSFYGRH for Etk, YIYGSFK for the other
kinases), and CTA095 (0–10 mM) were incubated in a kinase
reaction (100 mM Hepes, pH 7.4, 10 mM MnCl2, 10 mM
MgCl2, 1 mM DTT) for 5 min, and the reaction was started by
Figure 2. CTA095 is a potent Etk and Src dual inhibitor. The potency of CTA095 to Etk, Src, Btk and Yes was measured using TLC (A) to identify
33P-phosphorylated peptide substrate. Purified TKs (20 nM), CTA095 (0, 0.2, and 1 mM), and the peptide substrate (YIYGSFK) were incubated with 33P-
ATP in a kinase reaction. The resulting product was analyzed on a TLC plate. The effect of CTA095 to Etk autophosphorylation (B) was further
examined by incubation of Etk with CTA095 at the indicated concentrations in the presence of 33P-ATP, the radioactivity of Etk was measured using
radiosensitive film. The intensity of the radioactive spot was measured using densitometer. Columns, mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g002
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adding 5 mCi 33P-labeled ATP. The reaction (10 ml) was incubated
at room temperature for 1 h and was stopped by adding 10 mL
H3PO4. The radioactivity of the peptide substrate was analyzed
using TLC as previously described [27].
Etk autophosphorylation assay
Etk autophosphorylation activity was measured by an in vitro
kinase assay. Briefly, purified Etk (100 ng) was mixed with
CTA095 in the kinase assay buffer (20 mM Hepes pH 7.55,
10 mM MgCl2, 10 mM MnCl2, 1 mM DTT, 500 mM Na3VO4).
The cold ATP (5 mM) and hot r-33P-ATP (5 mCi) were added to
the mixture and the kinase reaction was performed at 30uC for
30 min. The reactions were terminated with a 4X SDS-PAGE
sample buffer, and then loaded onto an 8% SDS-polyacrylamide
gel for electrophoresis. The gel was vacuum dried and the ETK
auto kinase activity was analyzed with a phosphoimager (Biorad).
Cell culture
LNCAP, PC3, CWR22Rv1, and RWPE1 cells were maintained
in RPMI 1640 medium containing 10% fetal bovine serum and
1% penicillin/streptomycin/glutamine.
Western blotting
Western blotting was performed as described previously [28].
Proteins were detected using the following antibodies: b-actin
(Sigma-Aldrich, Saint Louis, MO), Etk (Santa Cruz Inc., Santa
Cruz, CA), pEtk; Src, pSrc; Stat3, pStat3. For phospho-Etk, cells
were pre-treated with 100 mM pervanadate for 15 min before
harvest.
MTT assay
Cells were seeded in 96-well plates and cultured overnight,
followed by treatment with 0.1% DMSO, as the vehicle control,
and CTA095, at the indicated concentrations for 72 h. Growth
inhibition was measured using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Roche Diagnostic,
Mannheim, Germany).
Flow cytometry
PC3 cells were treated with 0.1% DMSO (control) and CTA095
at the indicated concentrations for 24 h. Cell cycle arrest was
determined by the incorporation of propidium iodide (Sigma-
Aldrich) into permeabilized cells. Cells undergoing apoptosis were
identified using an Annexin V-FITC kit (Abcam), following the
manufacturer’s instructions. The cells were analyzed using a
Coulter Epics XL flow cytometer (Beckman Coulter, Miami, FL).
Analysis of Caspase-3/7 and caspase 9 activities
For caspase 3/7 activities, PC3 cells were seeded at 5,000 cells/
well in 96-well plate overnight. Then the cells were treated with 0–
10 mM CTA095 for 24 h. Caspase-3/7 activities were measured
using the Apo-ONE Homogeneous Caspase-3/7 Assay kit
(Promega, Madison, WI) according to the manufacturer’s instruc-
tion. For caspase 9 activity, PC3 cells were seeded in 10 mm tissue
culture plate and grew to 50% confluence. Cells were then treated
with 0–10 mM CTA095 for 24 h. Cells were harvested and
caspase 9 activity was measured using a Western blot with an anti-
caspase 9 antibody.
Autophagy assay
PC3 cells were stably transfected with GFP-LC3 [16]. Cells
were grown in a 6-well plate to 50% confluence and treated with
5 mM CTA095 for 24 h. Autophagy was visualized by GFP-LC3
‘‘puncta’’ and immunoblot of Endogenous LC3 isoforms.
HUVEC cell tube formation assay
HUVEC cells were seeded on mitrogel and treated with
CTA095 (0 and 5 mM) for 6 h. Vascular tube formation was
visualized using a microscope.
PC3 cell ‘‘Wound healing’’ assay
PC3 cells were grown in 6-well plate to 60% confluency. Then
wounds were made using a tip and treated with CTA095 (0 and
5 mM). Cell migration (wound healing) was visualized under
microscope at the indicated times.
Inhibition of PC3 xenograft tumor growth by
CTA095nano (CAT095 formulated in nano-micelles)
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of California, Davis
(Protocol Number: 16697). Briefly, 26106 PC3 cells were injected
subcutaneously to the flanks of 5 week-old male nude mice. Tumor
volume was measured by a caliper and calculated using the
formula V= (L6W2)1/2. The tumors were grown to the indicated
size and the mice were randomly divided into two groups (8 mice/
group). The control group was treated with vehicle. The treatment
group was treated with CTA095nano at 10 mg/kg twice a week
via i.v. injection. The tumor size and body weight were measured
once a week. The experiment was terminated when the tumor size
of the control group reached humane endpoints by IACUC.
Curves of tumor volumes verses duration were plotted for both
groups.
CTA095 overcomes Src inhibitor resistance in prostate
cancer cells
PC3 and PC3-AZD20 (PC3 cell resistant to 20 mM AZD0530,
which is from AstraZeneca through MTA with Dr. Chris Evans)
cells were seeded at 2000 cells/well in 96 well plates overnight.
The cells were treated with AZD0530 or CTA095 at the indicated
concentrations. Cell viability was measured using an MTT assay
after 72 h.
Table 1. Kinase inhibition profile of CTA095.
Kinase IC50 (mM)
Etk 0.06
Src 0.12
Btk 27
Yes .10
Itk .10
Lyn .10
Axl .10
Mer .10
EGFR .10
Abl .10
doi:10.1371/journal.pone.0070910.t001
Etk and Src Dual Inhibitor for Prostate Cancer
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CTA095 induces apoptosis in Src inhibitor resistant
prostate cancer cells through Myc and BCL2 inhibition
PC3-AZD20 cells were seeded at 106 cells/well in 6 well plates
overnight. The cells were treated with AZD0530 or CTA095 at
10 mM. Apoptosis was analyzed using Annexin-V FITC apoptosis
detection kit. The mRNA levels of Myc and BCL2 were measured
using real-time PCR. pEtk, Etk, pSrc, Src, pStat3, Stat3, Myc and
BCL2 levels were measured using the corresponding antibodies
through a Western blot.
Statistics
A one-way ANOVA was used in combination with a Tukey test
for pair wise comparison. P values less than 0.05 were considered
significant.
Results
CTA095 as a dual inhibitor against Etk and Src tyrosine
kinases
Through screening a 9,600-diversity combinatorial solution
phase small molecule library, hit compounds with inhibitory
activities against Etk were discovered. Subsequent structure-
activity-relationship studies led to the identification of CTA095
(Figure 1A). Compared with other CT compounds with a fused
three-ring core structure identical to CTA095, CTA095 showed
significant Etk inhibition (Figure 1B). Interestingly, there was a
strong correlation between Etk inhibition and PC3 growth
inhibition (Figure 1C). This data suggests that Etk may be the
target responsible for the growth inhibition observed for PC3 cells.
Having isolated a small molecule that inhibits Etk, the next
logical step was to determine its specificity for this enzyme. To
accomplish this, purified Etk, Btk, Src and Yes were incubated in a
kinase reaction buffer with CTA095 (0–1 mM) in the presence of
33P-labeled ATP and a peptide (YIYGSFK), previously shown to
be an excellent substrate for both BTK and Src family kinases.
The kinase activity was measured using TLC technique. This
study revealed that CTA095 was a potent inhibitor for Etk, with
an IC50 of approximately 60 nM (Figure 2A). Inhibition was
observed in a concentration dependent manner. Moreover,
CTA095 could also inhibit Src (IC50 < 120 nM). However, Btk
and Yes were significantly more resistant to CTA095 inhibition
with IC50 greater than 10 mM (Figure 2A, Figure S2).
Figure 3. Molecular Modeling of CTA095-Etk binding. (A) Surface view of Etk docked to CTA095 after 20 ns of MD minimization and relaxation.
R3 and the three-ring core docked deeper between Glycine-rich loop region (cyan) and hinge region (orange), R1 and R2 are solvent exposed. Blue:
Helix C; Red: Activation Loop; Green: DFG motif (554–556); Cyan: Glycine-rich loop; Orange; Hinge Region. (B) Cartoon representation showing
predicted interactions of CTA095 with the gatekeeper Thr489, DFG (554–556) motif, and Cys496. CTA095 binding stabilizes Phe555 in ‘out’
configuration, and affects the active state salt bridge formation between Lys445 and Glu460. Blue: Helix C; Red: Activation Loop; Green: DFG motif
(554–556); Cyan: Glycine-rich loop; Orange; Hinge Region. Figures were generated using PyMol.
doi:10.1371/journal.pone.0070910.g003
Figure 4. Inhibition of cell signaling in PC3 cells following
treatment with CTA095. Cells were grown in 10 mm plate to 50%
confluence and treated with CTA095. Cells were harvested after 24 h.
pEtk, Etk, pSrc, Src, pStat3, Stat3, pAkt and Akt levels were measured
using the corresponding antibodies by Western blot. One of three
similar experiments depicted.
doi:10.1371/journal.pone.0070910.g004
Etk and Src Dual Inhibitor for Prostate Cancer
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e70910
The Btk family of non-receptor tyrosine kinases is characterized
by the presence of an autophosphorylation site within the non-
catalytic Src homology 3 (SH3) domain. Thus, it was also
important to determine the ability of CTA095 to inhibit Etk
autophosphorylation. Therefore, an in vitro Etk autophosphoryla-
tion assay was established in which purified Etk was mixed with
CTA095 in the presence of 33P-ATP. After 30 min, the reaction
was terminated, and the samples were loaded onto an SDS-
polyacrylamide gel for electrophoresis. After drying, the gel was
analyzed with a phosphoimager. Figure 2B reveals that CTA095
was able to inhibit Etk autophosphorylation in a concentration
dependent manner.
In addition to the Btk family tyrosine kinases, the inhibitory
activity of CTA095 to other kinases, including Lyn, Axl, Mer,
EGFR, and Abl, was investigated using a TLC assay. As shown in
Table 1, CTA095 appears to have strong reactivity toward Etk
and Src, much higher than that of any other kinases tested.
Figure 5. Growth Inhibition of CTA095 to LNCAP, CWR22Rv1, PC3 prostate cancer and normal prostate (RWPE1) cells. Cells were
seeded at 5,000 cells/well in 96-well plate overnight and treated with CTA095 at the indicated concentrations. The cell viability was measured using
MTT assay after 72 h. dots, mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g005
Figure 6. Induction of autophagy in PC3 cells by CTA095. Cells were grown in 6-well plate to 50% confluence and treated with CTA095.
Autophagy was visualized by GFP-LC3 ‘‘puncta’’ (A) and immunoblot of Endogenous LC3 isoforms (B). All experiments were carried out 24 h after
treatment.
doi:10.1371/journal.pone.0070910.g006
Etk and Src Dual Inhibitor for Prostate Cancer
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CTA095 inhibits Etk through binding of its ATP binding
region
To explore the putative mechanism responsible for Etk
inhibition by CTA095, molecular docking and dynamics studies
were performed. These studies predict that CTA095 interacts with
the back-pocket of the ATP binding region. This binding pocket is
formed by the residues in the Glycine rich loop, ‘gatekeeper’
T489, and the hinge region (Figure 3A). The R3 group of CTA095
interacts with the gatekeeper molecule Thr489, and also stabilizes
the Phe555 of DFG motif in an inactive ‘out’ position (Figure 3B).
Moreover, the three-ring core group of the compound interacts
with the Cys496, which is very unique to the Etk. Only 8 kinases
out of the 491 kinases that were analyzed in a previous study
[29,30] show Threonine and Cysteine at these positions. Thus
CTA095’s interaction with both Thr489 and Cys496 may provide
it with unique kinase selectivity. We also used LigPlot+ to predict
hydrogen bonding and/or hydrophobic interactions in the binding
pocket, and our results showed that multiple hydrophobic
interactions are responsible for the CTA095-Etk binding (Figur-
e S3A and S3B). Side chains that putatively interact with CTA095
are shown in Figure S3C. Analysis of the molecular dynamics
trajectories also show that the R3 group and the three-ring core
interact strongly and stably with the side chains in the binding
pocket, while R1 and parts of R2 are solvent exposed, and may
serve as targets for further improvement of the CTA095 binding
and specificity (Movie S1).
Unlike ETK-CTA095 binding, Src kinase shows binding with
CTA095 in the active site pocket formed by the N-lobe, C-lobe
and the activation loop. CTA095 in its docked position spans the
residues Asp404 and Asn 391, which are both important for Mg2+
and ATP binding. CTA095 also putatively interacts with the
functionally important Tyr416 residue, which is part of the
activation loop region (Figure S4). Overall, we believe that
CTA095 blocks the ATP binding pocket in Src kinase, and
inhibits ATP binding in Etk by inducing conformational changes
via the back-pocket.
CTA095 inhibits the phosphorylation of Etk, Src and the
downstream signals Stat3 and Akt in prostate cancer
cells
The inhibitory activity of CTA095 against phosphorylation of
Etk in intact cells was examined by Western blot. Etk, as well as
Src phosphorylation in PC3-Etk (PC3 cells stably transfected with
Etk), cells were significantly inhibited at 5 mM and 10 mM. The
Src inhibition is likely to result from both direct inhibition by
CTA095, as well as the diminished activity Etk, which activates
Src. A selective target for Etk and Src is STAT3, whose
phosphorylation is also inhibited by CTA095. Akt is another
Figure 7. Induction of apoptosis of PC3 cells following treatment with CTA095. PC3 cells were seeded at 106 cells/ml (2 ml) in a 6-well plate
overnight and then treated with CTA095 at the indicated concentrations for 24 h. Cell cycle arrest was analyzed using PI staining (A). Apoptosis was
analyzed using Annexin-V FITC apoptosis detection kit (B). Caspase 9 activation was measured using western blot (D). For caspase 3/7 activity, PC3
cells were seeded at 5000 cells/well in 96 well plate overnight and treated with CTA095 at 0–10 mM for 24 h. Caspase-3/7 activities were measured
using the Apo-ONE Homogeneous Caspase-3/7 Assay kit (Promega, Madison, WI) according to the manufacturer’s instruction. Columns, mean; bars,
standard deviation, n = 3. 5 mM and 10 mM are significantly different from 0 mM (*, p,0.05, one-way ANOVA with Tukey test for pair wise
comparison).
doi:10.1371/journal.pone.0070910.g007
Etk and Src Dual Inhibitor for Prostate Cancer
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e70910
important downstream effector of Etk, and its phosphorylation was
inhibited by CTA095 (Figure 4).
CTA095 preferentially inhibits the growth of malignant
prostate cells
To determine the effect of CTA095 on proliferation, a panel of
cancer cell lines including LNCAP, CWR22Rv1, PC3 and the
normal prostate cell RWPE1 were incubated with CTA095 and
their proliferation was measured using the MTT assay. CTA095
was effective in inhibiting the growth of prostate cancer cells
(LNCAP, CWR22Rv1 and PC3), while the immortalized normal
prostate cell RWPE1 was more resistant to CTA095 (Figure 5),
likely due to the ‘‘addiction’’ to Etk signal by prostate cancer cells,
as shown previously [11].
CTA095 induces autophagy in prostate cancer cells
Previously we showed that the Src inhibitor AZD0530 induces
autophagy in prostate cancer cells, which contributes to apoptosis
resistance and diminishes the efficacy of the Src inhibitor [16]. To
determine whether CTA095 can trigger autophagy, PC3 cells
stably transfected with GFP-LC3 were treated with CTA095, then
examined under fluorescence microscopy. After 24 h treatment
with CTA095, these cells yielded extensive distinct ‘‘puncta’’
autophagosome morphology, whereas vehicle treatment did not
(Figure 6A). The ability of CTA095 to induce autophagy in PC3
cells was further confirmed by the conversion of endogenous LC3-
Figure 8. Inhibition of tube formation and cell migration by
CTA095. Inhibition of vascular tube formation of HUVEC endothelial
cells (A) and inhibition of migration (wound healing) of PC3 human
prostate cancer cells (B) by CTA095. (A) HUVEC cells were seed on
mitrogel and treated with CTA095 (0 and 5 mM) for 6 h. Vascular tube
formation was visualized using microscope. (B) PC3 cells were grown in
6-well plate to 60% confluency. Then wounds were made and treated
with CTA095 (0 and 5 mM). Cell migration (wound healing) was
visualized under microscope at the indicated times.
doi:10.1371/journal.pone.0070910.g008
Figure 9. CTA095 as a chemo sensitizer. Growth Inhibition of
CTA095 and in combination with 10 mM chloroquine (CQ), or 2 ng/ml
paclitaxel (PTX) to PC3 human prostate cancer cells. Cells were seeded
at 5,000 cells/well in 96-well plate overnight and pretreated with the
corresponding co-treatments for 1h, then treated with 2.5 mM CTA095.
The cell viability was measured using MTT assay after 72 h. Columns,
mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g009
Figure 10. Inhibition of PC3 xenograft tumor growth by
CTA095nano. (CAT095 formulated in nano-micelles.) 26106 PC3 cells
were injected subcutaneously to nude mice. The tumors were grown
the indicated size and the mice were randomly divided into two groups
(8 mice/group). The control group was treated with vehicle. The
treatment group was treated with CTA095nano at 10 mg/kg twice a
week with iv injection. The tumor size (A) and body weight (B) were
measured once a week. Marks, mean; bars, sd. n = 8.
doi:10.1371/journal.pone.0070910.g010
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I to LC3-II forms (Figure 6B). Thus, like the Src tyrosine kinase
inhibitor, inhibition of Etk also induces autophagy.
CTA095 induces apoptosis in prostate cancer cells
To determine whether the growth inhibition induced by
CTA095 on PC3 cells was due to apoptosis, flow cytometric
analysis was carried out. Following treatment with CTA095 for
24 h, a dose dependent accumulation of a ‘‘sub-G1’’ fraction was
observed using PI staining (Figure 7A). Data based on Annexin-V
reactivity also indicated a dose-dependent increase of apoptosis of
PC3 cells following treatment with CTA095 (Figure 7B). Further
investigation indicated that treatment of PC3 cells with CTA095
resulted in a dose dependent activation of caspase3/7 (Figure 7C)
and caspase 9 (Figure 7D). Thus, in contrast to the Src inhibitor
AZD05350, this Etk inhibitor induces a significant level of
apoptosis, despite its stimulation of the autophagy pathway. More
interestingly, 293 cells (Etk negative) are resistant to induce
apoptosis by CTA095, indicating the specificity of this compound
to Etk (Figure S5). As will be discussed later, Etk directly controls
the survival pathway, the absence of which apparently can
override the protective effect of autophagy. As a result, CTA095
induced apoptosis can be further enhanced by an autophagy
blockade (see below).
CTA095 inhibits HUVEC cell tube formation and prostate
cancer cell migration
Etk is highly expressed in endothelial cells and shown to be
involved in angiogenesis [31]. To investigate the ability of
CTA095 to inhibit angiogenesis, vascular tube formation of
HUVEC endothelial cells following treatment with CTA095 was
examined. As expected, tube formation of HUVEC cells was
disrupted by CTA095 (Figure 8A). To explore the ability of
CTA095 to inhibit cell migration, ‘‘wound healing’’ of PC3 cells
was measured following treatment with CTA095. As shown in
Figure 8B, ‘‘wound healing’’ of PC3 cells was greatly inhibited by
CTA095 after 48 h. These results suggest that CTA095 has the
ability not only to suppress prostate cancer cell growth, but also to
reduce angiogenesis.
CTA095 as a chemo-sensitizer
Our initial studies indicated that CTA095 has good cytotoxicity
toward a panel of prostate cancer cells. To examine whether Etk
and Src dual inhibitor works effectively as a chemo sensitizer, PC3
cells were co-treated with CTA095 and paclitaxel (PTX) (2ng/ml),
or the autophagy inhibitor chloroquine (CQ) (10 mM). Growth
inhibition was determined using an MTT assay after 72 h.
Interestingly, a synergistic effect of CTA095 with PTX or CQ to
prostate cancer cells was observed (Figure 9). This suggests that
CTA095 is a chemo sensitizer, and blocking of autophagy by CQ
promotes CTA095 induced cell death.
CTA095nano inhibits PC3 xenograft tumor growth in vivo
Given the in vitro activity of CTA095 against prostate cancer
cells, it is important to validate these results in vivo. Since CTA095
is highly insoluble in water, we formulated CTA095 into nano
micelles. This micelle was developed in our lab and has been used
successfully to formulate hydrophobic drugs such as paclitaxel and
vincristine [32,33]. As shown in Figure 10, CTA095nano
significantly prevented PC3 xenograft tumor growth at 10 mg/
kg (twice a week, intra-venous injection) without significant
toxicity.
CTA095 overcomes Src inhibitor resistance in prostate
cancer cells
Since CTA095 induces a significant amount of caspase
activation and apoptosis in prostate cancer cells, which is different
from the Src inhibitor AZD0530, we asked whether CTA095
could enhance the efficacy of Src inhibitors, and whether it could
overcome prostate cancer cell resistance developed toward this Src
inhibitor. A mixed population of AZD0530 resistant cells, PC3-
AZD20, was developed by long-term culture of PC3 cells with
gradually increasing AZD0530 concentrations up to 20 mM. PC3-
AZD20 cells were resistant to 20 mM AZD0530 (Figure 11A),
while highly sensitive to CTA095, with an IC50 almost identical to
that of the parental PC3 cells (Figure 11B). Massive apoptosis was
induced in PC3-AZD20 (PC3 cell resistant to 20 mM AZD0530)
cells following treatment with CTA095, but not with treatment of
AZD0530 (Figure 12A). These results suggest that the antiapopto-
tic activities conferred by Etk are involved in the resistance to Src
inhibitor and CTA095, as a dual inhibitor of Etk and Src,
counteract both anti-apoptosis effects.
CTA095 induces apoptosis in Src inhibitor resistant
prostate cancer cells through Myc and BCL2 inhibition
To explore the molecular basis of Src inhibitor resistance in
PC3-AZD20, cDNA microarrays were conducted for both PC3-
AZD20 and the parental PC3 cell line. Among the genes up-
regulated are c-myc and bcl-2. RT-PCR studies indicated that
Myc, as well as BCL2, were significantly down regulated in PC3-
AZD20 cells following treatment with CTA095 (Figure 12B),
indicating that this down regulation may contribute to the
induction of apoptosis in Src inhibitor resistant prostate cancer
cells. Interestingly, a Western blot indicated that pSrc and
pSTAT3, but not c-myc and Bcl-2 were decreased in PC3-
AZD20 cells following treatment with AZD0530. pEtk, pSrc,
pSTAT3, Myc and BCL2 were all down regulated following
Figure 11. CTA095 overcomes Src inhibitor resistance in
prostate cancer cells. PC3 and PC3-AZD20 (PC3 cell resistant to
20 mM AZD0530) cells were seeded at 2000 cells/well in 96 well plates
overnight. The cells were treated with AZD0530 or CTA095 at the
indicated concentrations. Cell viability was measured using MTT assay
after 72 h. Symbols, mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g011
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treatment with CTA095, implying that pEtk inhibition may lead
to down regulation of Myc and BCL2 and subsequent apoptosis
(Figure 12C). The more detailed signaling pathways between this
link remains to be further elucidated.
Discussion
Tyrosine kinases have become important targets for drug
development. Powerful combinatorial chemistry approaches and
high throughput screening assays have led to successful identifi-
cation of many kinase inhibitors [34–37]. AZD0530, an Src kinase
inhibitor, has been to shown to be effective in inhibiting prostate
cancer cell bone metastasis in animal models, but AZD0530 lacks
the activity to induce apoptosis. Previous work in our lab indicated
that Etk is complexed with Src and FAK, and that it plays an
important role in apoptosis, angiogenesis, and metastasis of
prostate cancer cells. While Src signals primarily regulate cell
growth, the Etk and FAK are involved in cell migration. In
addition, Etk interacts with p53 and controls the apoptosis
pathway. Inhibition of Src leads to cell cycle arrest and reduction
of migration and inhibition. Dual inhibition of Src and Etk are
expected to inhibit growth, migration, and survival of the cells. To
the best of our knowledge, this is the first selective Etk/Src
inhibitor reported to date.
CTA095 belongs to a novel class of kinase inhibitors with a
chemical structure distinct from other known TKIs. This inhibitor
is most potent in inhibiting Etk followed by Src, but it is not a
potent inhibitor for other Tec and Src family kinases such as Btk,
Yes and Lyn. Treatment of PC3 cells with CTA095 resulted in the
decrease of phoshorylation of Etk and Src, as well as the
downstream signals Stat3 and Akt. CTA095 has little effect on
the survival of the immortalized normal prostate cell RWPE1,
suggesting that the growth and survival of prostate cancer cells are
more dependent on Etk and Src signals, consistent with the
observed overexpression of Etk in prostate cancer tissues and the
development of PIN phenotype in transgenic animals carrying
overexpressed Etk [11]. Etk interacts with and inactivates p53, and
overexpression of Etk in prostate cancer cells confers resistance to
androgen deprivation [38] and photodynamic therapy [3]. On the
other hand, truncated Etk, due to caspase cleavage, induces
Figure 12. CTA095 induces apoptosis in Src inhibitor resistant prostate cancer cells through Myc and BCL2 inhibition. PC3-AZD20
(PC3 cell resistant to 20 mM AZD0530) cells were seeded at 106 cells/well in 6 well plates overnight. The cells were treated with AZD0530 or CTA095 at
10 mM. Apoptosis was analyzed using Annexin-V FITC apoptosis detection kit (A). The mRNA levels of Myc and BCL2 were measured using real-time
PCR (B). pEtk, Etk, pSrc, Src, pStat3, Stat3, Myc and BCL2 levels were measured using the corresponding antibodies through Western blot (C).
Columns, mean; bars, standard deviation, n = 3.
doi:10.1371/journal.pone.0070910.g012
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apoptosis [39]. This data taken together suggests that Etk is a
strong regulator of apoptosis. At the same time, CTA095 was
found to induce autophagy in human prostate cancer cells.
Autophagy is generally regarded as a pro-survival mechanism,
where wasted proteins and retired organs are degraded to
regenerate energy during stress conditions. It is inhibited by
energy sensor mTOR, a target of rapamycin (RPM). Excessive
autophagy, under special conditions, however, can lead to
programmed cell death (type II). Previously, we reported that
autophagy induced by Src inhibitor is the underlying cause of
apoptosis-resistance of the treated cells [16]. These cells are
growth arrested, but do not undergo apoptosis. Blocking
autophagy by siRNA targeting of autophagy components, or the
simultaneous application of CQ, an inhibitor of autophagy flow,
results in massive cell death. It is interesting that, like the Src
inhibitor, CTA095 induced autophagy is likely due to its inhibition
of mTOR activation. However, unlike the Src inhibitor, CTA095
inhibits both Etk and Src, and can overcome the apoptosis
resistance induced by autophagy. This data suggests that the
absence of Etk proactively turns on the apoptosis pathway, which
cannot be completely overridden by the restoring act of
autophagy. The finding that the autophagy inhibitor CQ further
enhances the apoptosis-inducing effect of CTA095 suggests that
autophagy contributes partially to the survival of CTA095 treated
cells. Alternatively, CQ is known to have other cellular effects
including induction of p53 and intercalation of DNA, which may
contribute additional toxicity to the treated cells. Curiously, we
found that the autophagy inducer RPM also synergizes with
CTA095, suggesting excessive autophagy may contribute addi-
tional means to kill prostate cancer cells. CTA095 was also a
chemo-sensitizer and showed synergistic effect with PTX, indicat-
ing its role in combination therapy for prostate cancer. In addition
to these findings, CTA095 was found to inhibit HUVEC cell tube
formation and ‘‘wound healing’’ of prostate cancer cells, implying
its role in inhibition of angiogenesis and metastasis of human
prostate cancer cells (Figure 13).
More interestingly, simultaneously targeting of Etk and Src by
CTA095 overcomes the Src inhibitor resistance in prostate cancer
cells. The Src inhibitor AZD0530 has a good effect on inhibition
of bone metastasis of prostate cancer, but lacks the ability to
induce apoptosis in prostate cancer cells. Dual inhibition of Etk
and Src could overcome this disadvantage and induce massive
apoptosis in Src inhibitor-resistant prostate cancer cells. This is
likely through the inhibition of Etk and down regulation of Myc
and BCL2. The more detailed signaling pathways between the link
remains to be further investigated.
In summary, we have identified an Etk and Src dual inhibitor,
CTA095, with good selectivity toward prostate cancer cells. This
inhibitor could overcome Src inhibitor resistance and induce
apoptosis in Src inhibitor-resistant prostate cancer cells. This study
indicates that Etk and Src dual inhibition holds exceptional
promise as a novel treatment strategy for prostate cancer.
Supporting Information
Figure S1 Synthetic scheme of CTA095.
(TIF)
Figure 13. Proposed signal pathways of CTA095 in prostate cancer cells.
doi:10.1371/journal.pone.0070910.g013
Etk and Src Dual Inhibitor for Prostate Cancer
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e70910
Figure S2 Inhibition of Btk by CTA095. Purified Btk (20
nM), CTA095 (0–100 mM), ATP (500 mM) and the peptide
substrate (YIYGSFK) were incubated in a kinase reaction. The
kinase activity was measured using Kinase-Glo assay kit (Promega
Inc.) following the manufacture’s instruction. Columns, mean;
bars, standard deviation, n = 3.
(TIF)
Figure S3 Predicted hydrophobic and hydrophilic in-
teractions between Etk and CTA095. Interactions between
CTA095 and Etk as predicted using LigPlot+ from MD
trajectories after (A) 10 ns of relaxation (B) 20 ns of relaxation.
Red dashed arrows: Hydrophobic interactions; Green: Hydrogen
bonding. (C) Putative interactions between CTA095 and ETK
residue side chains colored according to charge properties Green:
Polar; Orange: Non-Polar; Blue: Basic.
(TIF)
Figure S4 Molecular modeling of CTA095-Src binding.
(TIF)
Figure S5 Induction of apoptosis of 293 cells following
treatment with CTA095. 293 cells were seeded at 106 cells/ml
(2 ml) in a 6-well plate overnight and then treated with CTA095 at
the indicated concentrations for 24 h. Apoptosis was analyzed
using Annexin-V FITC apoptosis detection kit. Columns, mean;
bars, standard deviation, n= 3.
(TIF)
Movie S1 Molecular Dynamics Trajectory of Etk bound
to CTA095. Movie shows interactions between CTA095 (in
licorice representation) and side chains of Thr489 (gatekeeper
molecule), Asp554, Cys480, Phe555, Lys445 and Glu460 (shown
as sticks). Lime Green: Helix C; Light Blue: Activation Loop;
Orange: Glycine-rich loop; Movie generated using VMD.
(MPG)
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